Advertisement

Blood concentration of tacrolimus and age predict tacrolimus-induced left ventricular dysfunction after bone marrow transplantation in adults

  • Kohko KanazawaEmail author
  • Masumi Iwai-Takano
  • Satoru Kimura
  • Tetsuya Ohira
Original Article—Cardiology
  • 26 Downloads

Abstract

Purpose

Tacrolimus (TAC) is used for the prophylaxis and treatment of acute graft-versus-host disease after bone marrow transplantation (BMT). However, few have reported on TAC-induced left ventricular hypertrophy. This study aimed to assess the relationship between blood concentration of TAC and development of TAC-induced left ventricular (TI-LV) dysfunction in adult BMT patients with hematologic malignant diseases, and to evaluate whether TAC concentration can predict TI-LV dysfunction occurrence in these patients.

Methods

We enrolled 16 consecutive patients (mean age 44.6 ± 13.0 years) who received TAC after BMT. Echocardiography was performed before and after BMT, and blood concentrations of TAC were evaluated in terms of AUC15 (area sum of TAC > 15 ng/ml during follow-up). We assessed the relationship between AUC15 and development of TI-LV dysfunction after TAC.

Results

During the follow-up period (mean duration 47.6 ± 13.7 days), interventricular septum thickness (IVST, P = 0.001) and posterior wall thickness (PWT, P < 0.001) increased, and E′ decreased (P = 0.006). AUC15 was associated with post-IVST (R = 0.627, P = 0.009), post-PWT (R = 0.669, P = 0.005), and post-E′ (R = − 0.767, P = 0.001). In multivariate analysis, AUC15 and age independently predicted the increase in IVST and PWT and decrease in E′ after BMT. The combination of AUC15 and older age predicted post-PWT with a sensitivity of 77.8% and specificity of 71.4%.

Conclusion

TAC concentrations should be maintained at < 15 ng/ml and age should be considered in patients undergoing BMT to avoid TI-LV dysfunction.

Keywords

Tacrolimus-induced left ventricular dysfunction Bone marrow transplantation Echocardiography Hematologic malignant disease Adult 

Notes

Acknowledgements

I would like to express my deep gratitude to Dr. Yurie Saito, Dr. Hiroyuki Kambayashi, and Dr. Masahiko Fukatsu for their help in collecting clinical data.

Compliance with ethical standards

Conflicts of interest

Kohko Kanazawa, Masumi Iwai-Takano, Satoru Kimura, and Tetsuya Ohira declare that they have no conflicts of interest.

Ethical statements

This study was approved by the institutional review board of Ohta Nishinouchi Hospital, and it employed an opt-out consent approach. The study complied with the principles of the Declaration of Helsinki.

References

  1. 1.
    Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc. 1991;23:3225–7.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant. 1998;4:157–63.CrossRefGoogle Scholar
  3. 3.
    Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001;7:242–50.CrossRefGoogle Scholar
  4. 4.
    Boswell GW, Bekersky I, Fay J, et al. Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant. 1998;21:23–8.CrossRefGoogle Scholar
  5. 5.
    Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247–97.CrossRefGoogle Scholar
  6. 6.
    Oshima K, Sato M, Terasako K, et al. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT. Bone Marrow Transplant. 2010;45:781–2.CrossRefGoogle Scholar
  7. 7.
    Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345:894–6.CrossRefGoogle Scholar
  8. 8.
    Natazuka T, Ogawa R, Kizaki T, et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. Lancet. 1995;345:1644.CrossRefGoogle Scholar
  9. 9.
    Dhawan A, Mack DR, Langnas AN, et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. Lancet. 1995;345:1644–5.CrossRefGoogle Scholar
  10. 10.
    Chang RK, Alzona M, Alejos J, et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Pediatr Transplant. 2001;5:187–91.CrossRefGoogle Scholar
  11. 11.
    Seino Y, Hori M, Sonoda T. Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. Cardiovasc Drugs Ther. 2003;17:141–9.CrossRefGoogle Scholar
  12. 12.
    Takeuchi T, Ino K, Dohi K, et al. Tacrolimus-induced left ventricular apical hypertrophy in a patient with post-allogeneic hematopoietic stem cell transplantation. Int J Cardiol. 2014;177:e22–4.CrossRefGoogle Scholar
  13. 13.
    Espino G, Denney J, Furlong T, et al. Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. Bone Marrow Transplant. 2001;28:1097–103.CrossRefGoogle Scholar
  14. 14.
    Bowman LJ, Brennan DC, Delos-Santos R, et al. Tacrolimus-induced cardiomyopathy in an adult renal transplant recipient. Pharmacotherapy. 2015;35:1109–16.CrossRefGoogle Scholar
  15. 15.
    Nakata Y, Yoshibayashi M, Yonemura T, et al. Tacrolimus and myocardial hypertrophy. Transplantation. 2000;69:1960–2.CrossRefGoogle Scholar
  16. 16.
    Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society Of Echocardiography and the European Association Of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.CrossRefGoogle Scholar
  17. 17.
    Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.CrossRefGoogle Scholar
  18. 18.
    Jayaraman T, Brillantes AM, Timerman AP, et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem. 1992;267:9474–7.PubMedGoogle Scholar
  19. 19.
    Lam E, Martin MM, Timerman AP, et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J Biol Chem. 1995;270:26511–22.CrossRefGoogle Scholar
  20. 20.
    Atkison PR, Joubert GI, Guiraudon C, et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation. 1997;64:773–5.CrossRefGoogle Scholar
  21. 21.
    Timerman AP, Jayaraman T, Wiederrecht G, et al. The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein. Biochem Biophys Res Commun. 1994;198:701–6.CrossRefGoogle Scholar
  22. 22.
    Minamino T, Kitakaze M, Ueda Y, et al. Chronic Treatment with FK506 increases p70 S6 Kinase activity associated with reduced nitric oxide synthase activity in rabbit hearts. Cardiovasc Drugs Ther. 2000;14:329–36.CrossRefGoogle Scholar
  23. 23.
    Minamino T, Kitakaze M, Papst PJ, et al. Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy associated with the activation of p70 S6 kinase in rats. Cardiovasc Drugs Ther. 2000;14:533–42.CrossRefGoogle Scholar
  24. 24.
    Baruch Y, Weitzman E, Markiewicz W, et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. Transpl Proc. 1996;28:2250–1.Google Scholar
  25. 25.
    Jarzembowski TM, John E, Panaro F, et al. Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant. 2005;9:117–21.CrossRefGoogle Scholar
  26. 26.
    Mano A, Nakatani T, Yahata Y, et al. Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report. Transpl Proc. 2009;41:3831–4.CrossRefGoogle Scholar
  27. 27.
    Khanna A, Jain A, Ziady G, et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transpl Proc. 1997;29:532–3.CrossRefGoogle Scholar
  28. 28.
    Coley KC, Verrico MM, McNamara DM, et al. Lack of Tacrolimus-Induced Cardiomyopathy. Ann Pharmacother. 2001;35:985–9.CrossRefGoogle Scholar

Copyright information

© The Japan Society of Ultrasonics in Medicine 2019

Authors and Affiliations

  1. 1.Division of CardiologyOhta Nishinouchi HospitalKoriyamaJapan
  2. 2.Department of EpidemiologyFukushima Medical UniversityFukushimaJapan
  3. 3.Fukushima Prefectural General Hygiene InstituteFukushimaJapan
  4. 4.Division of Cardiovascular SurgeryFukushima Medical UniversityFukushimaJapan
  5. 5.Division of HematologyOhta Nishinouchi HospitalKoriyamaJapan

Personalised recommendations